Argatroban

Drug Profile

Argatroban

Alternative Names: Acova; Arganova; Argatra; Argipidine; Da Bei; DK 7419; Exembol; GN 1600; MCI-9038; MD 805; Novastan; OM 805; Slonnon

Latest Information Update: 02 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Mitsubishi Chemical
  • Developer Cardiome Pharma; Daiichi Sankyo Company; Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Europe; Novartis; University of Texas Health Science Center at Houston
  • Class Antithrombotics; Pipecolic acids; Small molecules
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Arterial thrombosis; Heparin-induced thrombocytopenia and thrombosis syndrome; Peripheral arterial occlusive disorders; Stroke
  • Preregistration Cerebral infarction
  • Discontinued Myocardial infarction; Unstable angina pectoris

Most Recent Events

  • 28 Feb 2017 Preregistration for Cerebral infarction in China (IV) (Mitsubishi Tanabe Pharma Corporation pipeline, July 2017)
  • 15 Apr 2016 Efficacy data from a phase II trial in Stroke presented at the 68th Annual Meeting of the American Academy of Neurology (AAN)
  • 30 Sep 2015 Cardiome Pharma and Mitsubishi Tanabe Pharma Europe agree to co-promote argatroban in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top